Welcome to our dedicated page for Abivax S.A. news (Ticker: ABVX), a resource for investors and traders seeking the latest updates and insights on Abivax S.A. stock.
Abivax SA (ABVX) generates frequent news flow as a clinical-stage biotechnology company advancing obefazimod (ABX464) for chronic inflammatory diseases, particularly inflammatory bowel disease. Company press releases focus on clinical trial milestones, scientific presentations, financial updates, and capital markets developments related to its programs in ulcerative colitis and Crohn’s disease.
Investors and observers following ABVX news can expect detailed updates on the ABTECT Phase 3 program in moderately to severely active ulcerative colitis, including induction and maintenance trial results, Data Safety Monitoring Board reviews, and analyses of efficacy, safety, and patient-reported outcomes. News items also cover the ENHANCE-CD Phase 2b induction trial in moderate-to-severely active Crohn’s disease and preclinical work on obefazimod’s anti-fibrotic activity in inflammatory bowel disease models.
Abivax regularly announces the acceptance and presentation of late-breaking abstracts and multiple scientific posters at major meetings such as the United European Gastroenterology (UEG) Congress and the European Crohn’s and Colitis Organization (ECCO) Congress. These news releases describe new clinical subgroup analyses, biomarker data, and quality-of-life outcomes, as well as symposia and educational events organized by the company.
On the corporate side, Abivax news includes financial results, descriptions of research and development spending, and information on equity offerings and index inclusions, such as admission to the CAC Mid 60, SBF 120, and Nasdaq Biotechnology Index. Together, these updates provide a view of how Abivax is progressing its lead asset obefazimod, managing its financial resources, and positioning itself within the biotechnology sector. Bookmark this page to review the latest ABVX press releases, clinical data announcements, and regulatory and capital markets communications in one place.
Abivax (NASDAQ:ABVX) announced late-breaking results from the Phase 3 ABTECT 8-week induction trials for obefazimod presented Oct 5, 2025 at UEG. The PR states the pooled 50 mg once-daily dose produced a 16.4% placebo-adjusted clinical remission rate at Week 8 (p<0.0001) and that both ABTECT 1 and 2 met the FDA primary endpoint and all key secondary endpoints at 50 mg.
The trials enrolled 1,272 patients with a refractory population (47% with prior inadequate response to advanced therapy; 21% with prior JAK inhibitor inadequate response). The PR reports no signal for serious, severe, or opportunistic infections or malignancies and provides updated TEAE rates by dose.
Abivax (NASDAQ:ABVX) announced the acceptance of a second late-breaking abstract for its lead drug candidate obefazimod at the 2025 United European Gastroenterology (UEG) Meeting. The presentations will showcase results from the ABTECT Phase 3 induction trials for treating moderately to severely active ulcerative colitis.
Two key presentations are scheduled: The first by Dr. Bruce Sands on October 5, focusing on efficacy and safety results from the 8-week induction trials (ABTECT-1 & 2), and the second by Dr. Silvio Danese on October 6, examining efficacy in patient subsets with and without prior inadequate response to advanced therapies. According to Chief Medical Officer Dr. Fabio Cataldi, the trials demonstrated statistically significant and clinically meaningful activity with an impressive safety profile.
Abivax (NASDAQ: ABVX) announced the upcoming presentation of a late-breaking abstract for obefazimod, their lead drug candidate for treating moderately to severely active ulcerative colitis (UC), at the 2025 United European Gastroenterology (UEG) Meeting in Berlin. The presentation, titled "Efficacy of Obefazimod in ABTECT Phase 3 Induction Trials," will take place on October 6, 2025, at 10:00 AM CET.
The company will host an analyst and investor call at 3 PM CET on the same day and conduct a symposium titled "From Evolution to Revolution: New Mechanisms in Ulcerative Colitis" at 5:30 PM CET. The presentation will focus on 8-week therapy results in patients with and without prior inadequate response to advanced therapies.
Abivax (Euronext: ABVX, Nasdaq: ABVX), a clinical-stage biotechnology company, has been selected to join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The inclusion will become effective on September 19, 2025, after market close.
The company, which focuses on developing therapeutics for chronic inflammatory diseases, expects this inclusion to enhance its visibility and broaden its investor base, particularly among institutional investors and index-linked funds. CEO Marc de Garidel highlighted this achievement as a validation of the company's strategic vision and execution capabilities.
Abivax (NASDAQ/Euronext: ABVX) reported its H1 2025 financial results, highlighting increased R&D investments and significant capital raising activities. The company recorded an operating loss of EUR 93.7M, up from EUR 80.0M in H1 2024, primarily due to expanded R&D expenses of EUR 77.9M.
Key developments include successful completion of a $747.5M public offering in July 2025 and positive Phase 3 results from ABTECT trials for obefazimod in ulcerative colitis. The company's cash position stood at EUR 60.9M as of June 30, 2025, and with recent financing activities, Abivax expects to fund operations into Q4 2027.
Notable debt conversions occurred post-period, including Heights Capital Management's conversion of EUR 21.9M convertible notes and Kreos Capital's conversion of Tranche A convertible OCABSA.
Abivax (NASDAQ/Euronext: ABVX), a clinical-stage biotechnology company, has successfully closed its public offering of 11,679,400 American Depositary Shares (ADSs), including the full exercise of the underwriters' option. The offering generated gross proceeds of $747.5 million (€637.5 million), with estimated net proceeds of $700.3 million (€597.2 million) after deducting costs.
The company expects these proceeds, combined with existing cash, will extend its operational runway into Q4 2027, providing 12 months of cash following the planned NDA submission for Ulcerative Colitis, contingent on positive Phase 3 maintenance trial results. The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities as joint bookrunners.
Abivax (NASDAQ:ABVX), a clinical-stage biotechnology company focused on chronic inflammatory diseases, announced the full exercise of underwriters' option to purchase 1,523,400 additional American Depositary Shares (ADSs) at $64.00 per ADS.
The additional shares bring the total offering to 11,679,400 ADSs, resulting in gross proceeds of $747.5 million (€637.5 million) and estimated net proceeds of $700.3 million (€597.2 million). The offering price represents a 21.0% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris over the last three trading sessions.
The closing is expected on July 28, 2025, with the net proceeds to be applied proportionally to the same purposes as the base offering.
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.
Abivax (NASDAQ:ABVX) has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per ADS, aiming to raise approximately $650 million. The company has also granted underwriters a 30-day option to purchase up to 1,523,400 additional ADSs.
The offering price represents a 21% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris. The proceeds will primarily fund the clinical development of obefazimod for Ulcerative Colitis ($140-185 million) and Crohn's Disease ($30-65 million). Combined with current cash reserves of $71.4 million, this funding is expected to extend operations into Q4 2027.
The offering will result in approximately 16% dilution of share capital, or 18.4% if the underwriters' option is fully exercised. A 60-day lock-up period applies to both company executives and the company itself.
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.
The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of €0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.